Vericel Corporation VCEL · SEC Filings

398

Vericel Corporation operates as a biopharmaceutical firm that has reached the commercialization phas...

Price58.39

Market Cap2.99 B

Float50.6 M

CountryUS

SectorHealthcare

ExchangeNASDAQ

Overview Filings Insights Dilution News Transcripts

Search in Documents

Open in Studio Login

Financials

TYPE

HEADLINE

FILED AT

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 5, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Jul 30, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 7, 2026

10-K

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Feb 26, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 6, 2025

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Jul 31, 2025

News

TYPE

HEADLINE

FILED AT

8-K

Vericel Reports Q3 2026 Financial Results and Raises Full-Year Guidance

Nov 5, 2026

8-K

Vericel Reports Second Quarter 2026 Financial Results, Raises Full-Year Guidance and Announces $200 Million Share Repurchase Program

Jul 30, 2026

8-K

Vericel Corporation Amends Bylaws to Reflect New Global Headquarters

May 18, 2026

8-K

Vericel Corporation Reports Q1 2026 Financial Results and Raises Full-Year Revenue Guidance

May 7, 2026

8-K

Vericel Corporation Announces Results of 2026 Annual Meeting of Shareholders

May 1, 2026

8-K

Vericel Reports Strong Q4 and Full-Year 2025 Financial Results with Significant Revenue and Net Income Growth

Feb 26, 2026

Prospectus

TYPE

HEADLINE

FILED AT

424B5

Form 424B5 - Prospectus [Rule 424(b)(5)]

Jun 1, 2018

424B5

Form 424B5 - Prospectus [Rule 424(b)(5)]

May 30, 2018

424B5

Form 424B5 - Prospectus [Rule 424(b)(5)]

Dec 16, 2016

424B5

Form 424B5 - Prospectus [Rule 424(b)(5)]

Dec 15, 2016

424B5

Form 424B5 - Prospectus [Rule 424(b)(5)]

Oct 11, 2016

424B5

Form 424B5 - Prospectus [Rule 424(b)(5)]

Jul 29, 2015

Registrations

TYPE

HEADLINE

FILED AT

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

May 8, 2025

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

May 8, 2025

S-3ASR

SHELF

Aug 16, 2024

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

May 22, 2023

S-8 POS

Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments

May 6, 2022

S-8 POS

Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments

May 6, 2022

Proxies

TYPE

HEADLINE

FILED AT

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Mar 19, 2026

DEF 14A

Form DEF 14A - Other definitive proxy statements

Mar 19, 2026

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Mar 20, 2025

DEF 14A

Form DEF 14A - Other definitive proxy statements

Mar 20, 2025

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Mar 21, 2024

DEF 14A

Form DEF 14A - Other definitive proxy statements

Mar 21, 2024

Ownerships

TYPE

HEADLINE

FILED AT

144

NEWForm 144 - Report of proposed sale of securities

Nov 9, 2026

144

NEWForm 144 - Report of proposed sale of securities

Nov 9, 2026

4

NEWMara Joseph Anthony Jr (Reporting)

Nov 9, 2026

144/A

Form 144/A - Report of proposed sale of securities: [Amend]

Nov 6, 2026

144

Form 144 - Report of proposed sale of securities

Nov 6, 2026

4

SIEGAL JONATHAN (Reporting)

Nov 6, 2026

Other

TYPE

HEADLINE

FILED AT

CT ORDER

Form CT ORDER - Confidential treatment order

Jan 19, 2022

LETTER

Form UPLOAD - SEC-generated letter

Nov 19, 2019

LETTER

Form UPLOAD - SEC-generated letter

Nov 19, 2019

CORRESP

Form CORRESP - Correspondence

Nov 13, 2019

LETTER

Form UPLOAD - SEC-generated letter

Nov 5, 2019

LETTER

Form UPLOAD - SEC-generated letter

Nov 5, 2019